Key facts
- RyboDyn’s last known valuation is $49.0M (Mar 2026).
- It has raised $13.9M; the latest was Seed Round ($10.0M) in Mar 2026.
- Notable investors include SOSV, IndieBio, Massive Tech Ventures, EvoNexus, Genedant Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for RyboDyn
- ·The full record, as it builds
Funding rounds
No funding rounds for RyboDyn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RyboDyn
Developer of front-running scientific breakthroughs designed to develop upgraded medicines. The company's scientific breakthroughs a new class of treatments for far-reaching improvements, enabling individuals to get treated for terminal diseases and ailments.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2022
- Employees
- 9
- Website
- rybodyn.com/
- Ownership
- Privately Held (backing)
RyboDyn doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RyboDyn shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RyboDyn in its N-PORT filings yet. We sweep new filings monthly.